


PRODUCT INFORMATION



Tafluprost (free acid)

Item No. 10005439

CAS Registry No.: 209860-88-8
Formal Name: (5Z)-7-[(1R,2R,3R,5S)-2-[(1E)-3,3-difluoro-4-phenoxy-1-buten-1-yl]-3,5-dihydroxycyclopentyl]-5-heptenoic acid
Synonym: AFP-172
MF: C₂₂H₂₈F₂O₅
FW: 410.5
Purity: ≥98%
UV/Vis.: λ_{max}: 269, 276 nm
Supplied as: A solution in methyl acetate
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Tafluprost (free acid) is supplied as a solution in methyl acetate. To change the solvent, simply evaporate the methyl acetate under a gentle stream of nitrogen and immediately add the solvent of choice. Solvents such as ethanol, DMSO, and dimethyl formamide purged with an inert gas can be used. The solubility of tafluprost (free acid) in these solvents is approximately 30 mg/ml.

Tafluprost (free acid) is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, the methyl acetate solution of tafluprost (free acid) should be diluted with the aqueous buffer of choice. The solubility of tafluprost (free acid) in PBS (pH 7.2) is approximately 3 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

Tafluprost (free acid) is an FP receptor agonist (K_i = 4 nM for the human receptor), a derivative of prostaglandin F_{2α} (PGF_{2α}; Item Nos. 16010 | 16020), and an active metabolite of the prodrug tafluprost (Item No. 10005440).¹ It is formed from tafluprost by hydrolysis and is selective for the FP receptor over the dopamine receptor and PGE₂ receptor subtypes EP₁ and EP₂, as well as a panel of 32 neurological receptors and transporters, at 1 μM. Tafluprost (free acid) induces constriction in isolated cat iris sphincters (EC₅₀ = 0.6 nM).² It also increases the proliferation and migration of, capillary formation by, and COX-2 levels in, human umbilical vein endothelial cells (HUVECs) when used at a concentration of 100 μM.³

References

1. Takagi, Y., Nakajima, T., Shimazaki, A., *et al.* Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. *Exp. Eye Res.* **78(4)**, 767-776 (2004).
2. Nakajima, T., Matsugi, T., Goto, W., *et al.* New fluoroprostaglandin F_{2α} derivatives with prostanoid FP-receptor agonistic activity as potent ocular-hypotensive agents. *Biol. Pharm. Bull.* **26(12)**, 1691-1695 (2003).
3. Roh, Y.J., Park, Y.G., Kang, S., *et al.* Effects of AFP-172 on COX-2-induced angiogenic activities on human umbilical vein endothelial cells. *Graefes Arch. Clin. Exp. Ophthalmol.* **250(12)**, 1765-1775 (2012).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 02/21/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM